Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease. [PDF]
Alzheimers DementCai Y +15 more
europepmc +1 more source
Label-Free Detection of Cellular Aβ Accumulation and Mitochondrial Dysfunction in AD Cell Models via Raman Microscopy. [PDF]
Anal ChemMitsuoka Y +5 more
europepmc +1 more source
Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers. [PDF]
Alzheimers Dement (Amst)Noh MY +7 more
europepmc +1 more source
Six-month real-world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia. [PDF]
Alzheimers Dement (N Y)Kim GH +7 more
europepmc +1 more source
Sustaining Drug Discovery Amid the Limits of Alzheimer's Disease Immunotherapies. [PDF]
eNeuroMcDiarmid A.
europepmc +1 more source
CellSwarm-AD: A Multi-Scale Agent-Based Framework for Virtual Alzheimer's Disease Trials. [PDF]
Int J Mol SciTan CL +5 more
europepmc +1 more source
Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain. [PDF]
Alzheimers DementGrenon MB +5 more
europepmc +1 more source
Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series. [PDF]
Front PsychiatryHan J, Fang Y, Esiaka D, Abraham O.
europepmc +1 more source
Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community. [PDF]
Neurol SciSantos DH, da Silva AMP.
europepmc +1 more source